![]() One responder requested an alternative novel oral anticoagulant (NOAC) be listed for patients who have an intolerance to dabigatran. PHARMAC will work with wholesalers and suppliers as per our usual practice when implementing price changes. One responder requested price support to minimise the potential for an out-of-stock situation. Supportive of idarucizumab listing, noting the lack of alternatives and likely health benefits. All responses were supportive of the proposal: Theme All consultation responses received by 8 July 2016 were considered in their entirety in making a decision on the proposed changes. We appreciate all of the feedback that we received and acknowledge the time people took to respond.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |